One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease
doi : 10.1093/ibd/izae138
Inflammatory Bowel Diseases, Volume 31, Issue 4, April 2025, Pages 903–911
Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments Open Access
doi : 10.1093/ibd/izae290
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program Open Access
doi : 10.1093/ibd/izae111
Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era
doi : 10.1093/ibd/izae113
Endoscopic Balloon Dilatation of Ileal Pouch-Anal Anastomosis Strictures in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
doi : 10.1093/ibd/izae128
Mortality of Patients With Inflammatory Bowel Disease in the Faroe Islands From 1966-2020
doi : 10.1093/ibd/izae120
Identification of the M2 Macrophage-associated Gene THBS2 as a Predictive Marker for Inflammatory Cancer Transformation
doi : 10.1093/ibd/izae129
Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets Open Access
doi : 10.1093/ibd/izae123
Integrating the Patient Perspective to Validate a Measure of Disease Severity in Inflammatory Bowel Disease: Online Survey of Patients and Their Physicians
doi : 10.1093/ibd/izae127
Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing
doi : 10.1093/ibd/izae152
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis Open Access
doi : 10.1093/ibd/izae136
High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data
doi : 10.1093/ibd/izae148
Invasive Therapeutic Strategies for Stricturing Crohn’s Disease in Childhood: A Systematic Review and Meta-Analysis
doi : 10.1093/ibd/izae144
IBD Is Like a Tree: Reflections From Older Adults With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae139
Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation Open Access
doi : 10.1093/ibd/izae255
A Similar Mutation in the AAUU-Rich Elements of the Mouse TNF Gene Results in a Distinct Ileocolitic Phenotype: A New Strain of TNF-Overexpressing Mice
doi : 10.1093/ibd/izae307
Inflammation-Induced Th17 Cells Synergize with the Inflammation-Trained Microbiota to Mediate Host Resiliency Against Intestinal Injury
doi : 10.1093/ibd/izae293
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study Open Access
doi : 10.1093/ibd/izae278
Escherichia coli Nissle Improves Short-Chain Fatty Acid Absorption and Barrier Function in a Mouse Model for Chronic Inflammatory Diarrhea Open Access
doi : 10.1093/ibd/izae294
Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes
doi : 10.1093/ibd/izae185
Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update
doi : 10.1093/ibd/izae189
TOpClass Class 4 Perineal Crohn’s Disease: A Systematic Review and Meta-analysis of Perineal Wound Complication After Proctectomy in Crohn’s Patients
doi : 10.1093/ibd/izae198
Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis Open Access
doi : 10.1093/ibd/izaf006
Risk of Paradoxical Rheumatoid Arthritis in Inflammatory Bowel Disease Patients Exposed to Tumor Necrosis Factor Inhibitors: A Propensity-Matched Multicenter Study
doi : 10.1093/ibd/izae203
Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis
doi : 10.1093/ibd/izae215
The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases
doi : 10.1093/ibd/izae248
Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab Open Access
doi : 10.1093/ibd/izae259
Altered Bile Acids and Pouch Microbiota Composition in Patients With Chronic Pouchitis
doi : 10.1093/ibd/izaf005
Postpartum Wound Healing for Mothers with Inflammatory Bowel Disease: Cause for Worry? Insights from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Registry
doi : 10.1093/ibd/izae309
Opioids Intertwined With Psychology: Hidden Effects in the Treatment of Patients With IBD
doi : 10.1093/ibd/izae300
Reply: Opioids Intertwined With Psychology: Hidden Effects in the Treatment of Patients With IBD
doi : 10.1093/ibd/izae305
